New drugs in the therapy of neuroendocrine tumors.

摘要: Neuroendocrine tumors (NET) are a rare and heterogeneous group of neoplasms relatively indolent nature whose incidence prevalence increasing. Despite the advances made in field NET over past years, these eventually progress to metastatic disease most patients, with fatal outcome majority. Traditional cytotoxic agents remain limited efficacy; however, recently, better understanding molecular pathways has provided clues potential targets for new therapeutic strategies. Somatostatin analogs well known be useful control symptoms functioning tumors, it was recently demonstrated that they can inhibit tumor progression certain settings. Moreover, published randomized trials multi-TKI sunitinib mTOR-inhibitor everolimus have demonstrated, first time, their ability positively impact natural history pancreatic (PNET). In this short review, we will discuss available data on newer targeted treatment advanced well-differentiated gastro-entero-pancreatic (GEP-NET). A possible algorithm use treatments context extreme heterogeneity GEP-NET presentation proposed.